Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells

Virology

Volumn 404, Issue 2, 2010, Pages 231-239

  Zwilling, Joachim ^a   Sliva, Katja ^a   Schwantes, Astrid ^a   Schnierle, Barbara ^a   Sutter, Gerd ^a,b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

F11L; Host range; K1L; MVA; Vaccinia virus

Indexed keywords

ANIMAL CELL; ARTICLE; CELL MOTILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VACCINIA VIRUS; VIRAL GENETICS; VIRION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; CELL LINE; CELL MOVEMENT; CHICK EMBRYO; CRICETINAE; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; HELA CELLS; HUMANS; MICE; MUTATION; RABBITS; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 77954541066     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.05.008     Document Type: Article

References (37)

1. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244:365-396.
2. Arakawa Y., Cordeiro J.V., Way M. F11L-mediated inhibition of RhoA-mDia signaling stimulates microtubule dynamics during vaccinia virus infection. Cell Host Microbe 2007, 1:213-226.
3. Backes S., Sperling K.M., Zwilling J., Gasteiger G., Ludwig H., Kremmer E., Schwantes A., Staib C., Sutter G. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha. J. Gen. Virol. 2010, 91:470-482.
4. Boulanger D., Baier R., Erfle V., Sutter G. Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategy. J. Virol. Meth. 2002, 106:141-151.
5. Bradley R.R., Terajima M. Vaccinia virus K1L protein mediates host-range function in RK-13 cells via ankyrin repeat and may interact with a cellular GTPase-activating protein. Virus Res. 2005, 114:104-112.
6. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238:198-211.
7. Cordeiro J.V., Guerra S., Arakawa Y., Dodding M.P., Esteban M., Way M. F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS ONE 2009, 4:e8506.
8. Donaldson J.G. Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. J. Biol. Chem. 2003, 278:41573-41576.
9. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 1998, 79(Pt 2):347-352.
10. Gallego-Gomez J.C., Risco C., Rodriguez D., Cabezas P., Guerra S., Carrascosa J.L., Esteban M. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J. Virol. 2003, 77:10606-10622.
11. Hornemann S., Harlin O., Staib C., Kisling S., Erfle V., Kaspers B., Hacker G., Sutter G. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 2003, 77:8394-8407.
12. Lin S., Broyles S.S. Vaccinia protein kinase 2: a second essential serine/threonine protein kinase encoded by vaccinia virus. Proc. Natl. Acad. Sci. U S A 1994, 91:7653-7657.
13. Ludwig H., Suezer Y., Waibler Z., Kalinke U., Schnierle B.S., Sutter G. Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. J. Gen. Virol. 2006, 87:1145-1155.
14. Mayr A. TC marker of the attenuated vaccinia vaccide strain "MVA" in human cell cultures and protective immunization against orthopox diseases in animals. Zentralbl. Veterinärmed. B 1976, 23:417-430.
15. Mayr A., Munz E. Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl. Bakteriol. Orig. 1964, 195:24-35.
16. Meiser A., Boulanger D., Sutter G., Krijnse Locker J. Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release. J. Gen. Virol. 2003, 84:1383-1392.
17. Meng X., Xiang Y. Vaccinia virus K1L protein supports viral replication in human and rabbit cells through a cell-type-specific set of its ankyrin repeat residues that are distinct from its binding site for ACAP2. Virology 2006, 353:220-233.
18. Meng X., Jiang C., Arsenio J., Dick K., Cao J., Xiang Y. Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J. Virol. 2009, 83:10627-10636.
19. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72(Pt 5):1031-1038.
20. Morales I., Carbajal M.A., Bohn S., Holzer D., Kato S.E.M., Greco F.A.B., Moussatche N., Locker J.K. The vaccinia virus F11L gene product facilitates cell detachment and promotes migration. Traffic 2008, 9:1283-1298.
21. Perkus M.E., Goebel S.J., Davis S.W., Johnson G.P., Limbach K., Norton E.K., Paoletti E. Vaccinia virus host range genes. Virology 1990, 179:276-286.
22. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: a Laboratory Manual 1989, Cold Spring Harbor Lab Press, Plainview, NY.
23. Shisler J.L., Jin X.L. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J. Virol. 2004, 78:3553-3560.
24. Staib C., Drexler I., Ohlmann M., Wintersperger S., Erfle V., Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 2000, 28:1137-1142.
25. Staib C., Lowel M., Erfle V., Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques 2003, 34:694-696.
26. Staib C., Drexler I., Sutter G. Construction and isolation of recombinant MVA. Meth. Mol. Biol. 2004, 269:77-100.
27. Steidl S., Schule S., Muhlebach M.D., Stitz J., Boller K., Cichutek K., Schweizer M. Genetic engineering of onco/lentivirus hybrids results in formation of infectious but not of replication-competent viruses. J. Gen. Virol. 2004, 85:665-678.
28. Stickl H.A. Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA". Prev. Med. 1974, 3:97-101.
29. Stickl H., Hochstein-Mintzel V. Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus ("MVA virus"). Münch. Med. Wochenschr. 1971, 113:1149-1153.
30. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U S A 1992, 89:10847-10851.
31. Sutter G., Ramsey-Ewing A., Rosales R., Moss B. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J. Virol. 1994, 68:4109-4116.
32. Sutter G., Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 2003, 3:263-271.
33. Valderrama F., Cordeiro J.V., Schleich S., Frischknecht F., Way M. Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling. Science 2006, 311:377-381.
34. Ward B.M., Moss B. Vaccinia virus intracellular movement is associated with microtubules and independent of actin tails. J. Virol. 2001, 75:11651-11663.
35. Werden S.J., Rahman M.M., McFadden G. Poxvirus host range genes. Adv Virus Res. 2008, 135-171.
36. Willis K.L., Patel S., Xiang Y., Shisler J.L. The effect of the vaccinia K1 protein on the PKR-eIF2alpha pathway in RK13 and HeLa cells. Virology 2009, 394:73-81.
37. Wyatt L.S., Carroll M.W., Czerny C.P., Merchlinsky M., Sisler J.R., Moss B. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 1998, 251:334-342.